Durvalumab plus enfortumab vedotin improves survival outcomes in muscle-invasive bladder cancer
read at onclive ↗Positive readoutPositive
A recent clinical study evaluated the perioperative use of durvalumab together with enfortumab vedotin in patients with muscle-invasive bladder cancer.
The topline results indicated that the combination improved both event-free survival and overall survival when compared with the current standard of care.
These positive efficacy signals suggest the regimen could become a new treatment option for this high-risk disease, pending further validation.
source
This writeup was produced by pharmadog from original reporting by onclive. The original article may no longer be reachable at its published URL.
Original headline: “Perioperative Durvalumab Plus Neoadjuvant EV Displays EFS, OS Benefits vs SOC in MIBC”
read at onclive ↗
comments(0)
5-min edit window · permanent after that